Bolognese to Provide Statistical Design of Biomarker-Driven Phase 2b Human Efficacy Study in Severe Community-Aquired Pneumonia

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – June 15, 2013) BioAegis Therapeutics announced today that it has engaged Jim Bolognese, Senior Director of Strategic Consulting at Cytel Inc., a leading firm in the design and conduct of adaptive trials. Prior to joining Cytel, Jim Bolognese worked for Merck & Company for 37 years designing clinical trials in various indications.